Lymphocyte Activation Gene 3 (LAG-3)

Joel C. Sunshine, Evan Lipson

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Lymphocyte activation gene 3 (LAG-3, CD223) is a protein expressed on the surface of activated T cells, regulatory T cells (Treg), natural killer (NK) cells, B cells, and plasmacytoid dendritic cells. LAG-3 signaling inhibits T cell activation and enhances regulatory T cell function (Camisaschi et al. 2010; Grosso et al. 2007; Joosten et al. 2007; Park et al. 2012). Like other molecules such as cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and T cell immunoglobulin mucin-3 (TIM-3), LAG-3 has attracted interest in oncology for its role as a negative regulator of T cell activation - an immunological "checkpoint" - that may play a role in helping tumors evade effective immune surveillance. This chapter will present a brief discussion of the molecular structure and biologic function of LAG-3 as a therapeutic target. The current role of LAG-3 in cancer with attention to pertinent preclinical and clinical data will be described. Finally, the potential impact and future directions of research into the optimal use of LAG-3 as a therapeutic target will be presented.

Original languageEnglish (US)
Title of host publicationCancer Therapeutic Targets
PublisherSpringer New York
Pages375-383
Number of pages9
Volume1-2
ISBN (Electronic)9781441907172
ISBN (Print)9781441907165
DOIs
StatePublished - Jan 1 2017

Fingerprint

Lymphocytes
Lymphocyte Activation
T-cells
Genes
Chemical activation
T-Lymphocytes
Regulatory T-Lymphocytes
Mucin-3
CTLA-4 Antigen
Molecular Structure
Natural Killer Cells
Dendritic Cells
Oncology
Immunoglobulins
Neoplasms
B-Lymphocytes
Molecular structure
Tumors
Cells
Therapeutics

Keywords

  • Cancer
  • Immunotherapy
  • LAG-3
  • T cell

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Sunshine, J. C., & Lipson, E. (2017). Lymphocyte Activation Gene 3 (LAG-3). In Cancer Therapeutic Targets (Vol. 1-2, pp. 375-383). Springer New York. https://doi.org/10.1007/978-1-4419-0717-2_136

Lymphocyte Activation Gene 3 (LAG-3). / Sunshine, Joel C.; Lipson, Evan.

Cancer Therapeutic Targets. Vol. 1-2 Springer New York, 2017. p. 375-383.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sunshine, JC & Lipson, E 2017, Lymphocyte Activation Gene 3 (LAG-3). in Cancer Therapeutic Targets. vol. 1-2, Springer New York, pp. 375-383. https://doi.org/10.1007/978-1-4419-0717-2_136
Sunshine JC, Lipson E. Lymphocyte Activation Gene 3 (LAG-3). In Cancer Therapeutic Targets. Vol. 1-2. Springer New York. 2017. p. 375-383 https://doi.org/10.1007/978-1-4419-0717-2_136
Sunshine, Joel C. ; Lipson, Evan. / Lymphocyte Activation Gene 3 (LAG-3). Cancer Therapeutic Targets. Vol. 1-2 Springer New York, 2017. pp. 375-383
@inbook{24537a58ca024684af39471dfef85cdc,
title = "Lymphocyte Activation Gene 3 (LAG-3)",
abstract = "Lymphocyte activation gene 3 (LAG-3, CD223) is a protein expressed on the surface of activated T cells, regulatory T cells (Treg), natural killer (NK) cells, B cells, and plasmacytoid dendritic cells. LAG-3 signaling inhibits T cell activation and enhances regulatory T cell function (Camisaschi et al. 2010; Grosso et al. 2007; Joosten et al. 2007; Park et al. 2012). Like other molecules such as cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and T cell immunoglobulin mucin-3 (TIM-3), LAG-3 has attracted interest in oncology for its role as a negative regulator of T cell activation - an immunological {"}checkpoint{"} - that may play a role in helping tumors evade effective immune surveillance. This chapter will present a brief discussion of the molecular structure and biologic function of LAG-3 as a therapeutic target. The current role of LAG-3 in cancer with attention to pertinent preclinical and clinical data will be described. Finally, the potential impact and future directions of research into the optimal use of LAG-3 as a therapeutic target will be presented.",
keywords = "Cancer, Immunotherapy, LAG-3, T cell",
author = "Sunshine, {Joel C.} and Evan Lipson",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-1-4419-0717-2_136",
language = "English (US)",
isbn = "9781441907165",
volume = "1-2",
pages = "375--383",
booktitle = "Cancer Therapeutic Targets",
publisher = "Springer New York",

}

TY - CHAP

T1 - Lymphocyte Activation Gene 3 (LAG-3)

AU - Sunshine, Joel C.

AU - Lipson, Evan

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Lymphocyte activation gene 3 (LAG-3, CD223) is a protein expressed on the surface of activated T cells, regulatory T cells (Treg), natural killer (NK) cells, B cells, and plasmacytoid dendritic cells. LAG-3 signaling inhibits T cell activation and enhances regulatory T cell function (Camisaschi et al. 2010; Grosso et al. 2007; Joosten et al. 2007; Park et al. 2012). Like other molecules such as cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and T cell immunoglobulin mucin-3 (TIM-3), LAG-3 has attracted interest in oncology for its role as a negative regulator of T cell activation - an immunological "checkpoint" - that may play a role in helping tumors evade effective immune surveillance. This chapter will present a brief discussion of the molecular structure and biologic function of LAG-3 as a therapeutic target. The current role of LAG-3 in cancer with attention to pertinent preclinical and clinical data will be described. Finally, the potential impact and future directions of research into the optimal use of LAG-3 as a therapeutic target will be presented.

AB - Lymphocyte activation gene 3 (LAG-3, CD223) is a protein expressed on the surface of activated T cells, regulatory T cells (Treg), natural killer (NK) cells, B cells, and plasmacytoid dendritic cells. LAG-3 signaling inhibits T cell activation and enhances regulatory T cell function (Camisaschi et al. 2010; Grosso et al. 2007; Joosten et al. 2007; Park et al. 2012). Like other molecules such as cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and T cell immunoglobulin mucin-3 (TIM-3), LAG-3 has attracted interest in oncology for its role as a negative regulator of T cell activation - an immunological "checkpoint" - that may play a role in helping tumors evade effective immune surveillance. This chapter will present a brief discussion of the molecular structure and biologic function of LAG-3 as a therapeutic target. The current role of LAG-3 in cancer with attention to pertinent preclinical and clinical data will be described. Finally, the potential impact and future directions of research into the optimal use of LAG-3 as a therapeutic target will be presented.

KW - Cancer

KW - Immunotherapy

KW - LAG-3

KW - T cell

UR - http://www.scopus.com/inward/record.url?scp=85038925705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038925705&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-0717-2_136

DO - 10.1007/978-1-4419-0717-2_136

M3 - Chapter

AN - SCOPUS:85038925705

SN - 9781441907165

VL - 1-2

SP - 375

EP - 383

BT - Cancer Therapeutic Targets

PB - Springer New York

ER -